Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06646302

Residual Inhibition of 40 Hz Burst Sound in Tinnitus Patients

Conditions: Tinnitus

Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Phase: NA
Enrollment: 363
Sponsor: Eye & ENT Hospital of Fudan University

Location: Eye & ENT Hospital of Fudan University Shanghai Shanghai Municipality

Summary

Tinnitus affects 10-15% of adults and is frequently associated with impaired quality of life, anxiety, and sleep disturbance. Conventional sound therapies based on continuous masking provide inconsistent and short-lived relief, and the neural mechanisms underlying residual inhibition (RI) remain unclear. This study aims to determine whether 40 Hz burst stimulation with high-frequency carriers can achieve longer-lasting RI than continuous sound, and to explore its underlying neural mechanisms using EEG.

Eligibility Criteria

Inclusion Criteria: 1. Diagnosed with subjective tinnitus; 2. Chronic tinnitus: tinnitus course ≥ 1 month; 3. Normal middle ear function; 4. The average hearing threshold (defined as mean of 0.5, 1, 2, and 4 kHz) of the unaffected ear \< 60 dB; 5. Tinnitus can be heard under normal circumstances. 6. Subjects are able to understand the purpose of the study, volunteer to participate and cooperate with the instructors to complete the experiment, and be willing to sign the informed consent. Exclusion Criteria: 1. Acute phase tinnitus; 2. Fluctuating tinnitus loudness; 3. Severe psychiatric disorders; 4. Inability to complete tinnitus testing; 5. Fluctuating or retrocochlear hearing loss; 6. Conductive hearing loss; 7. Currently participating in other research projects that may affect tinnitus; 8. Subjects who are not considered suitable for this clinical trial by the researchers.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06646302). StuddyBuddy aggregates publicly available trial information.